Literature DB >> 6377997

A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months.

.   

Abstract

Of 1,019 Chinese patients with radiologically active pulmonary tuberculosis but with sputum negative for acid-fast bacilli on 5 initial microscopic examinations who were studied for 5 yr, 364 (36%) had 1 or more initial sputum cultures positive for Mycobacterium tuberculosis. All 1,019 patients were randomly allocated to (1) selective chemotherapy (antituberculosis chemotherapy not being started until the disease had been confirmed to be active); or to (2) daily streptomycin, isoniazid, rifampin, and pyrazinamide for 2 months; or (3) for 3 months; or to (4) a standard 12-month control regimen. In the 364 patients with 1 or more of their initial sputum cultures positive, the short-course regimens were inadequate, being followed by relapse rates of 32 and 13%, respectively, during 60 months, compared with 5% in the control series. In the 655 patients with all their initial cultures negative, the corresponding relapse rates were 11, 7, and 2%. In the selective chemotherapy series, 57% of the patients had treatment started during the 60 months because their disease was confirmed to be active.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6377997     DOI: 10.1164/arrd.1984.130.1.23

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  20 in total

1.  M. tuberculosis intramembrane protease Rip1 controls transcription through three anti-sigma factor substrates.

Authors:  Joseph G Sklar; Hideki Makinoshima; Jessica S Schneider; Michael S Glickman
Journal:  Mol Microbiol       Date:  2010-06-01       Impact factor: 3.501

Review 2.  Pharmacokinetic factors in the modern drug treatment of tuberculosis.

Authors:  J G Douglas; M J McLeod
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

Review 3.  Current and potential treatment of tuberculosis.

Authors:  S Houston; A Fanning
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

4.  Drug tolerance in Mycobacterium tuberculosis.

Authors:  R S Wallis; S Patil; S H Cheon; K Edmonds; M Phillips; M D Perkins; M Joloba; A Namale; J L Johnson; L Teixeira; R Dietze; S Siddiqi; R D Mugerwa; K Eisenach; J J Ellner
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 5.  Treatment of tuberculous infection and disease in children: the North American perspective.

Authors:  C D Stowe; R F Jacobs
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.930

6.  Study of bronchoalveolar lavage in clinically and radiologically suspected cases of pulmonary tuberculosis.

Authors:  Usha Kalawat; Krishna K Sharma; Prakash N R Reddy; A Gururaj Kumar
Journal:  Lung India       Date:  2010-07

7.  Why is long-term therapy required to cure tuberculosis?

Authors:  Lynn E Connolly; Paul H Edelstein; Lalita Ramakrishnan
Journal:  PLoS Med       Date:  2007-03       Impact factor: 11.069

Review 8.  Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.

Authors:  Dick Menzies; Andrea Benedetti; Anita Paydar; Sarah Royce; Pai Madhukar; William Burman; Andrew Vernon; Christian Lienhardt
Journal:  PLoS Med       Date:  2009-09       Impact factor: 11.069

Review 9.  Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis.

Authors:  Dick Menzies; Andrea Benedetti; Anita Paydar; Ian Martin; Sarah Royce; Madhukar Pai; Andrew Vernon; Christian Lienhardt; William Burman
Journal:  PLoS Med       Date:  2009-09-15       Impact factor: 11.069

10.  Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis.

Authors:  Mariam O Fofana; Gwenan M Knight; Gabriela B Gomez; Richard G White; David W Dowdy
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.